Nektar Therapeutics Presents Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358 at 2019 Annual Meeting of the American College of Rheumatology
Go back to Nektar Therapeutics Presents Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358 at 2019 Annual Meeting of the American College of Rheumatology| Nektar Therapeutics (NASDAQ: NKTR) | Delayed: 67.10 -1.26 (1.84%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $68.36 | 52 Week High | $19.98 | |||
| Open | $68.00 | 52 Week Low | $10.52 | |||
| Day High | $69.09 | P/E | N/A | |||
| Day Low | $66.98 | EPS | $-1.45 | |||
| Volume | 2,806,723 | |||||
